Page 243 - Presents News Today

(0) - Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3K/mTOR and BCL signaling detected, suggesting potential patient benefit of combining gedatolisib with a BCL inhibitor - MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patien...

Tackling the climate crisis requires action from governments and polluters. What about us?

CRANSTON, RHODE ISLAND, UNITED STATES, April 5, 2021 /EINPresswire.com/ -- The Barrett Group ® (TBG) career management firm invites visitors to explore its new website. The new website has been carefully designed to offer a user-friendly experience with improved navigation and functionality. The new site, accessible via https://www.careerchange.com/, is easier to navigate, loads faster, and provides more information than the previous one. It is also mor...

TOYOTA GAZOO Racing Presents World Debut of the New GR 86 Toyota City, Japan, Apr 5, 2021 - (JCN Newswire) - On April 5, 2021, TOYOTA GAZOO Racing (TGR) gave the new GR 86 its world debut in an online event held together with Subaru Corporation (Subaru). Following the GR Supra and GR Yaris, the new GR 86 is the third global model in TGRs GR series of sports cars. The new GR 86 is scheduled to launch in Japan in autumn 2021. Toyota developed the original 86 with the goal of delivering the dreams...

Clariant AG: Clariant presents its Integrated Report 2020 Focus on Clariants environmental, social and governance performance Complete report available online, short report available as hard copy Muttenz, March 17, 2021- Clariant, a focused, sustainable and innovative specialty chemical company, today published its Integrated Report 2020. It provides transparency on the companys multidimensional approach to create value for all of its stakeholders by reviewing both tangible and intangible as we...

https://immatics.com/: Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs · cancer · Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products · Houston, Texas and Tuebingen, Germany, March 17, 2021 - Immatics N.V.(NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immun...

Mitazalimab synergizes with chemotherapy - Alligator Bioscience presents new preclinical data at AACR Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that an abstract for a poster presentation at the AACR (American Association for Cancer Research) Annual Meeting 2021, presenting new preclinical data for the clinical asset mitazalimab, is now released. The AACR Annual Meeting 2021 will be held in a virtual format over two one-week periods in April and May 2021. Alligator Bioscienc...

Photo Credit: IANS IANSLive Mumbai, March 10 (IANS)   The Farhan Akhtar-starrer boxing drama Toofaan is all set to release digitally on May 21. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 10-March-2021

UN presents Best Negotiator Award to Special Envoy of Foreign Minister  10 Mar 2021 - 8:32 Special Envoy of the Minister of Foreign Affairs for Counterterrorism and Mediation in Conflict Resolution, H E Dr. Mutlaq bin Majed Al Qahtani, participating in the event. QNA Geneva: The United Nations presented the 2020 Best Negotiator Award to Special Envoy of the Minister of Foreign Affairs for Counterterrorism and Mediation in Conflict Resolution H E Dr. Mutlaq bin Majed Al Qahtani, in recogniti...

10 marzo 2021 09:05 Fonte: Adnkronos #chimica-e-farmacia TAICHUNG, March 10, 2021 /PRNewswire/ -- Alar Pharmaceuticals Inc. (TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces positive interim results from the single-ascending-dose study of ALA-1000. A 3-month buprenorphine released injectable designed to be dosed subcutaneously for treating opioid use disorder (OUD). The Buprenorphine relea...